Fluconazole dose of 800 mg daily is required to reach antifungal plasma levels
This article has no abstract so we have provided the first paragraph of the full text.
Fungal septicemia caused by Candida spp. is treated with fluconazole. In vitro testing of the effects of fluconazole on Candida spp. indicated that plasma levels of 16–32 
g/ml are necessary to inhibit growth of some Candida spp. effectively. In patients receiving continuous veno-venous hemofiltration or continuous veno-venous hemodialysis, trials of fluconazole infusions of 200–600 mg/day failed to reach the required plasma concentration. Researchers in Germany attempted to determine whether a fluconazole dose of 800 mg/day would produce the required plasma concentration in nine intensive-care patients receiving continuous veno-venous hemofiltration for acute renal failure.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
